New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Novazyme Pharmaceuticals Inc.
Division of Sanofi
www.novazyme.com
Latest From Novazyme Pharmaceuticals Inc.
Trump Criticizes FDA For 'Slow' Approvals In Speech To Congress
In his first address to a joint session of Congress, Trump spoke of a need to "slash the restraints" at US FDA and other regulatory agencies, and he reminded legislators about his executive order to eliminate two regulations for each new one written. The president's anti-regulatory posture comes as the White House is expected to seek budget cuts for domestic agencies.
Trump Slams FDA Regulations In Joint Session Of Congress
US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.
Deal Statistics Quarterly, Q3 2001
In Vivo presents another installment of our quarterly review of dealmaking--in this case July 2001-September 2001. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Sanofi
- Senior Management
- John F Crowley, Pres. & CEO
- Contact Info
-
Novazyme Pharmaceuticals Inc.
Phone: (405) 271-8144
800 Research Pkwy Ste 200
Oklahoma City, OK
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novazyme Pharmaceuticals Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice